Global update on the susceptibility of humam influenza viruses to neuraminidase inhibitors 2012-2013
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.18/2934 |
Resumo: | Emergence of influenza viruses with reduced susceptibility to neuraminidase inhibitors (NAIs) is sporadic, often follows exposure to NAIs, but occasionally occurs in the absence of NAI pressure. The emergence and global spread in 2007/2008 of A(H1N1) influenza viruses showing clinical resistance to oseltamivir due to neuraminidase (NA) H275Y substitution, in the absence of drug pressure, warrants continued vigilance and monitoring for similar viruses. Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 11,387 viruses collected by WHO-recognized National Influenza Centres (NIC) between May 2012 and May 2013 to determine 50% inhibitory concentration (IC50) data for oseltamivir, zanamivir, peramivir and laninamivir. The data were evaluated using normalized IC50 fold-changes rather than raw IC50 data. Nearly 90% of the 11,387 viruses were from three WHO regions: Western Pacific, the Americas and Europe. Only 0.2% (n=27) showed highly reduced inhibition (HRI) against at least one of the four NAIs, usually oseltamivir, while 0.3% (n=39) showed reduced inhibition (RI). NA sequence data, available from the WHO CCs and from sequence databases (n=3661), were screened for amino acid substitutions associated with reduced NAI susceptibility. Those showing HRI were A(H1N1)pdm09 with NA H275Y (n=18), A(H3N2) with NA E119V (n=3) or NA R292K (n=1) and B/Victoria-lineage with NA H273Y (n=2); amino acid position numbering is A subtype and B type specific. Overall, approximately 99% of circulating viruses tested during the 2012-2013 period were sensitive to all four NAIs. Consequently, these drugs remain an appropriate choice for the treatment and prophylaxis of influenza virus infections. |
id |
RCAP_25d388689b596179a0303b4dbf1859fb |
---|---|
oai_identifier_str |
oai:repositorio.insa.pt:10400.18/2934 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
|
spelling |
Global update on the susceptibility of humam influenza viruses to neuraminidase inhibitors 2012-2013Antiviral ResistanceGlobal AnalysisInfluenza VirusNeuraminidase InhibitorsNormalization Using Fold-change DataOseltamivirResistência aos AntimicrobianosEmergence of influenza viruses with reduced susceptibility to neuraminidase inhibitors (NAIs) is sporadic, often follows exposure to NAIs, but occasionally occurs in the absence of NAI pressure. The emergence and global spread in 2007/2008 of A(H1N1) influenza viruses showing clinical resistance to oseltamivir due to neuraminidase (NA) H275Y substitution, in the absence of drug pressure, warrants continued vigilance and monitoring for similar viruses. Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 11,387 viruses collected by WHO-recognized National Influenza Centres (NIC) between May 2012 and May 2013 to determine 50% inhibitory concentration (IC50) data for oseltamivir, zanamivir, peramivir and laninamivir. The data were evaluated using normalized IC50 fold-changes rather than raw IC50 data. Nearly 90% of the 11,387 viruses were from three WHO regions: Western Pacific, the Americas and Europe. Only 0.2% (n=27) showed highly reduced inhibition (HRI) against at least one of the four NAIs, usually oseltamivir, while 0.3% (n=39) showed reduced inhibition (RI). NA sequence data, available from the WHO CCs and from sequence databases (n=3661), were screened for amino acid substitutions associated with reduced NAI susceptibility. Those showing HRI were A(H1N1)pdm09 with NA H275Y (n=18), A(H3N2) with NA E119V (n=3) or NA R292K (n=1) and B/Victoria-lineage with NA H273Y (n=2); amino acid position numbering is A subtype and B type specific. Overall, approximately 99% of circulating viruses tested during the 2012-2013 period were sensitive to all four NAIs. Consequently, these drugs remain an appropriate choice for the treatment and prophylaxis of influenza virus infections.Elsevier Masson/ International Society for Antiviral ResearchRepositório Científico do Instituto Nacional de SaúdeMeijer, A.Rebelo-de-Andrade, H.Correia, V.Besselaar, T.Drager-Dayal, R.Fry, A.Gregory, V.Gubareva, L.Kageyama, T.Lankenby, A.Lo, J.Odagiri, T.Pereyaslov, D.Siqueira, M.Takashita, E.Tashiro, M.Wang, D.Wong, S.Zhang, W.Daniels, R.Hurt, A.2015-02-19T16:20:08Z2014-102014-10-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.18/2934engAntiviral Res. 2014 Oct;110:31-41. doi: 10.1016/j.antiviral.2014.07.001. Epub 2014 Jul 170166-354210.1016/j.antiviral.2014.07.001info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-20T15:39:17ZPortal AgregadorONG |
dc.title.none.fl_str_mv |
Global update on the susceptibility of humam influenza viruses to neuraminidase inhibitors 2012-2013 |
title |
Global update on the susceptibility of humam influenza viruses to neuraminidase inhibitors 2012-2013 |
spellingShingle |
Global update on the susceptibility of humam influenza viruses to neuraminidase inhibitors 2012-2013 Meijer, A. Antiviral Resistance Global Analysis Influenza Virus Neuraminidase Inhibitors Normalization Using Fold-change Data Oseltamivir Resistência aos Antimicrobianos |
title_short |
Global update on the susceptibility of humam influenza viruses to neuraminidase inhibitors 2012-2013 |
title_full |
Global update on the susceptibility of humam influenza viruses to neuraminidase inhibitors 2012-2013 |
title_fullStr |
Global update on the susceptibility of humam influenza viruses to neuraminidase inhibitors 2012-2013 |
title_full_unstemmed |
Global update on the susceptibility of humam influenza viruses to neuraminidase inhibitors 2012-2013 |
title_sort |
Global update on the susceptibility of humam influenza viruses to neuraminidase inhibitors 2012-2013 |
author |
Meijer, A. |
author_facet |
Meijer, A. Rebelo-de-Andrade, H. Correia, V. Besselaar, T. Drager-Dayal, R. Fry, A. Gregory, V. Gubareva, L. Kageyama, T. Lankenby, A. Lo, J. Odagiri, T. Pereyaslov, D. Siqueira, M. Takashita, E. Tashiro, M. Wang, D. Wong, S. Zhang, W. Daniels, R. Hurt, A. |
author_role |
author |
author2 |
Rebelo-de-Andrade, H. Correia, V. Besselaar, T. Drager-Dayal, R. Fry, A. Gregory, V. Gubareva, L. Kageyama, T. Lankenby, A. Lo, J. Odagiri, T. Pereyaslov, D. Siqueira, M. Takashita, E. Tashiro, M. Wang, D. Wong, S. Zhang, W. Daniels, R. Hurt, A. |
author2_role |
author author author author author author author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório Científico do Instituto Nacional de Saúde |
dc.contributor.author.fl_str_mv |
Meijer, A. Rebelo-de-Andrade, H. Correia, V. Besselaar, T. Drager-Dayal, R. Fry, A. Gregory, V. Gubareva, L. Kageyama, T. Lankenby, A. Lo, J. Odagiri, T. Pereyaslov, D. Siqueira, M. Takashita, E. Tashiro, M. Wang, D. Wong, S. Zhang, W. Daniels, R. Hurt, A. |
dc.subject.por.fl_str_mv |
Antiviral Resistance Global Analysis Influenza Virus Neuraminidase Inhibitors Normalization Using Fold-change Data Oseltamivir Resistência aos Antimicrobianos |
topic |
Antiviral Resistance Global Analysis Influenza Virus Neuraminidase Inhibitors Normalization Using Fold-change Data Oseltamivir Resistência aos Antimicrobianos |
description |
Emergence of influenza viruses with reduced susceptibility to neuraminidase inhibitors (NAIs) is sporadic, often follows exposure to NAIs, but occasionally occurs in the absence of NAI pressure. The emergence and global spread in 2007/2008 of A(H1N1) influenza viruses showing clinical resistance to oseltamivir due to neuraminidase (NA) H275Y substitution, in the absence of drug pressure, warrants continued vigilance and monitoring for similar viruses. Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 11,387 viruses collected by WHO-recognized National Influenza Centres (NIC) between May 2012 and May 2013 to determine 50% inhibitory concentration (IC50) data for oseltamivir, zanamivir, peramivir and laninamivir. The data were evaluated using normalized IC50 fold-changes rather than raw IC50 data. Nearly 90% of the 11,387 viruses were from three WHO regions: Western Pacific, the Americas and Europe. Only 0.2% (n=27) showed highly reduced inhibition (HRI) against at least one of the four NAIs, usually oseltamivir, while 0.3% (n=39) showed reduced inhibition (RI). NA sequence data, available from the WHO CCs and from sequence databases (n=3661), were screened for amino acid substitutions associated with reduced NAI susceptibility. Those showing HRI were A(H1N1)pdm09 with NA H275Y (n=18), A(H3N2) with NA E119V (n=3) or NA R292K (n=1) and B/Victoria-lineage with NA H273Y (n=2); amino acid position numbering is A subtype and B type specific. Overall, approximately 99% of circulating viruses tested during the 2012-2013 period were sensitive to all four NAIs. Consequently, these drugs remain an appropriate choice for the treatment and prophylaxis of influenza virus infections. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-10 2014-10-01T00:00:00Z 2015-02-19T16:20:08Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.18/2934 |
url |
http://hdl.handle.net/10400.18/2934 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Antiviral Res. 2014 Oct;110:31-41. doi: 10.1016/j.antiviral.2014.07.001. Epub 2014 Jul 17 0166-3542 10.1016/j.antiviral.2014.07.001 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier Masson/ International Society for Antiviral Research |
publisher.none.fl_str_mv |
Elsevier Masson/ International Society for Antiviral Research |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
|
repository.mail.fl_str_mv |
|
_version_ |
1777303619745349632 |